In the 2026 China PIII, RemeGen ranked 6th in Innovation and 24th in Invention. The company continued to advance the commercial translation of its innovation, with market expansion of its established products and progress in international collaboration supporting its development. Against the backdrop of the company optimizing its R&D portfolio and deepening international collaboration, in 2025 RemeGen adjusted its pipeline in line with R&D resource reallocation. This strategic move reflects the company's current approach of balancing operational development with long-term innovation.

RemeGen's innovation is progressively translating into product revenue and operating results. In 2025, operating revenue reached RMB 3.251 billion, up 89.36% YoY, including product sales of RMB 2.307 billion and technology licensing revenue of RMB 895 million. Its two core innovative products, telitacicept (Tai'ai®) and disitamab vedotin (Aidixi®), were key revenue drivers, and product sales growth together with licensing revenue enabled the company to achieve full-year profitability. On the R&D front, the company invested RMB 1.219 billion during the year, supporting further clinical development...

Download the report to see the full company profile.